



The Japanese patent office intends to grant BioInvent's important patent relating to the immune-oncology antibody BI-1206

Lund, Sweden – 12 September 2017 – BioInvent International AB (OMXS: BINV) announces today that the Japanese patent office has decided that the company's first patent application relating to the immune-oncology antibody BI-1206 now can proceed to grant. The patent will be granted once all remaining administrative actions, such as payment of fees, have been completed by BioInvent. This patent is important since it covers the use of the company's drug candidate BI-1206, and similar CD32b antibodies, in combination with a CD19 or CD20 antibody, such as rituximab, in the treatment of cancer or inflammatory diseases in certain groups of patients.

This will be the third patent granted in this patent family, after the patents granted in Australia and by the European Patent Office. There are also corresponding patent applications pending in other countries.

Notes to editors:

About BioInvent

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company's clinical programmes are BI-1206, currently in a Phase I/II for non-Hodgkin's lymphoma and chronic lymphatic leukaemia and TB-403, in cooperation with Oncurios, currently in Phase I/II for medulloblastoma. BioInvent has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. In December 2016, the Company signed a strategic research collaboration with Pfizer Inc. BioInvent also works with leading academic institutions including the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent generates revenues from global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to late-stage clinical trials. More information is available at www.bioinvent.se

For further information, please contact:

Michael Oredsson
President and CEO
+46 (0)46 286 85 67
+46 (0)707 16 89 30
michael.oredsson@bioinvent.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 5.15 p.m. CET, on 12 September, 2017.

